• Summary
  • Table Of Content
  • Segmentation
  • Request sample

Global Antiviral Drugs Market Overview

Global Antiviral Drugs Market was valued at USD 64.11 Billion in 2023 and is expected to reach USD 96.93 Billion by the year 2032, at a CAGR of 4.7%.

Antiviral drugs are a class of medication that is used to kill or suppress the ability of a virus to replicate hence it prohibits the virus potential to proliferate and reproduce. Viruses are made of genetic material such as DNA or RNA which is alive when it is outside in the environment but gains its ability to reproduce and proliferate when it enters a susceptible host. In addition, antiviral drugs can prevent and protect individuals from getting viral infections or spreading the virus to others. Moreover, the development of antivirals is the outcome of newly acquired knowledge of the molecular and genetic activity of organisms letting us better apprehend the structure and function of viruses, chief advances in the techniques for finding novel drugs, and the stress placed on the medical sector to deal with the human immunodeficiency virus (HIV), the cause of acquired immunodeficiency syndrome is propelling the market growth in the period of forecast.

According to Statista, the global antiviral drug market is anticipated to reach 75 billion US dollars in 2027 from 52 billion US dollars in 2019. Additionally, there are many viruses which to date don't have antiviral drugs to treat the cause such as Rabies and HIV. According to WHO, 37.7 million people were living with HIV in 2020. Furthermore, to provide relief from viral diseases antiviral drugs are used, they significantly reduce the symptoms hence helps the infected individual to feel better, these factors are promoting the growth of the antiviral drugs market throughout the forecast.

 

COVID-19 Impact on Antiviral Drugs Market

The COVID-19 outbreak has significantly increased the demand for antiviral drugs globally. Moreover, COVID-19 disease has instigated governments to increase funding for research and development of antiviral drugs. COVID-19 has spurred the demand for antiviral drugs. Moreover, COVID-19 is an infectious viral disease of the upper respiratory tract hence it has a positive impact on the antiviral drug market. Furthermore, a government-imposed ban on transportation and the number of workers presents in antiviral drug manufacturing companies caused a small yet considerable impact on the production and supply chain.

Market Dynamics And Factors of Antiviral Drugs Market

Drivers:

The advantages of antiviral drugs are that they can cure some viral illnesses like hepatitis C or decrease the course of other viral illnesses like influenza. Antiviral drugs can be used to prevent the outbreak of certain viral illnesses like herpes. Moreover, characteristics of anti-viral drugs such as they can enter the cell infected with the virus and interfere with viral nucleic acid synthesis and thus restrict the virus ability to reproduce and proliferate in number thus, strengthening the growth of the anti-viral drugs market in the period o forecast. Furthermore, there has been a significant rise in the number of viral disease outbreaks in recent times hence to reduce future outbreaks there is a need for antiviral drugs hence strengthening the expansion of the antiviral drug market throughout the forecast.

Viral disease like smallpox is no longer a threat to the human population due to global vaccination programs. Furthermore, Polio caused by poliovirus is on the verge of extinction due to the wide-scale of antiviral drugs incorporated to prevent poliovirus from infecting healthy individuals. All these notable factors are promoting the use of antiviral drugs to prevent and eradicate viral diseases. Moreover, the increasing number of HIV, herpes, influenza, and other viral infections are driving the antiviral drug market. Furthermore, an increase in research and development activities for generating novel and advance formulations, such as vaccines, broad-spectrum antiviral drugs, and combination therapies to treat viral infection is propelling the antiviral drugs market.

Restraints:

Modern science technology has reached record height due to the research and development going on in this sector since the mid-20th century. Despite the rigorous research to find antivirals the arsenal of antivirals drugs remains dangerously small. Additionally, only about 100 antiviral drugs are available in the US market. Moreover, the lack of rapid diagnostic tests to identify viruses is hampering the antiviral drugs market in the period of forecast. Furthermore, the safety of antiviral drugs is a matter of concern. Moreover, a tremendous amount of money is utilized for manufacturing drugs which results in high pricing of antiviral drugs hence restraining the growth of the antiviral drugs market during the period of forecast. Antiviral drug resistance is a growing concern in immunocompromised individual populations, where ongoing viral replication and prolonged drug exposure results in the development of resistant strains. Moreover, WHO has reported cases of resistance to most antivirals including antiretroviral (ARV) drugs which are used to treat HIV thus hindering the antiviral drug market development in the span of the forecast. Furthermore, the growing trend of alternative medicines such as naturopathy and homeopathy are restraining the growth of the antiviral drug market throughout the forecast period.

Challenges:

To test the safety and efficiency of antiviral drugs, they are given to healthy individuals, however, sometimes it can cause adverse life-threatening situations thus trials on healthy individuals are the major challenge for the antiviral drug manufacturer. Moreover, urbanization has resulted in zoonosis (transfer of diseases from animals to humans) which has affected several economies worldwide. Furthermore, analyzing the disease-causing viral organism and producing antiviral drugs against it within a short period is one of the vital challenges for market players. In addition, on average to develop a novel antiviral drug takes around 10 to 15 years thus to reduce the time involved in research and developing effective antiviral drugs in a limited period is the biggest challenge for market players involved in antiviral drug manufacturing.

Opportunities:

The increasing number of viral infections and the growing demand for antiviral drugs is the major opportunity for market players. Moreover, several governments are investing huge funds in research and development to provide antiviral drugs to their population hence providing ample opportunities for market players. Developing broad-spectrum antiviral drugs with promising effects is a vital opportunity for market players.

Market Segmentation

Segmentation Analysis of Antiviral Drugs Market:

Based on Drug Action Mechanisms, Reverse Transcriptase Inhibitors are anticipated to have the highest share in the antiviral drugs market. The increasing number of HIV patients globally and the efficiency of these medicines to treat HIV infection are the key factors promoting the use of Reverse Transcriptase Inhibitors. Protease inhibitors are expected to have the second-highest share in the antiviral drug market owing to their ability to block the spread of HIV to uninfected cells.

Based on Application, the HIV segment is expected to dominate the antiviral drug market owing to the increasing cases of HIV patients. HIV followed by Hepatitis is estimated to have the second-largest share in the antiviral drug market owing to vaccination against Hepatitis A and Hepatitis B.

Based on Type, the antiviral drug market is segmented into branded and generic. The branded segment is estimated to dominate the antiviral drug market throughout the forecast owing to priorities given to branded drugs considering their effectiveness and almost negligible side effects. The generic segment is also expected to have significant growth in developing and underdeveloped countries owing to low prices and having almost the same efficacy as branded medicines.

Based on Age Group, the Geriatric segment is anticipated to lead the market owing to the increasing geriatric population and the high risk associated to contract the virus.

Regional analysis of Antiviral Drugs Market:

Depending on geography, the antiviral drug market is segmented into 5 regions North America, Middle East, and Africa, Asia­-Pacific, Europe, and South America.

North America is anticipated to dominate the antiviral drug market in the period of forecast owing to the enhanced and well-developed healthcare sector. Furthermore, the U.S. government is undertaking several measures including investment in infectious diseases programs and encouraging the R&D activities of innovative therapies to manage viral infections.

Asia-Pacific region is expected to grow at the fastest growth rate owing to the increasing prevalence and treatment rate of viral infections, developing healthcare sector, increasing number of research institutes, and increasing health awareness among people about infectious diseases.

Europe region is estimated to have a positive growth rate in the period of forecast. The well-developed healthcare sector, presence of major research institutes is propelling the antiviral drug market in this region.

Players Covered in Antiviral Drugs Market are:

  • Gilead Sciences Inc (US)
  • GlaxoSmithKline plc (UK)
  • Johnson & Johnson Services Inc (US)
  • AstraZeneca (UK)
  • AbbVie Inc (US)
  • Merck & Co Inc (US)
  • Teva Pharmaceutical Industries Ltd (Israel) Regeneron Pharmaceuticals Inc (US)
  • Bristol-Myers Squibb Company (US)
  • Zydus Cadila (India)
  • Cipla Inc (India)
  • Prinston Pharmaceutical Inc (US)
  • Hetero (India)
  • Aurobindo Pharma (India)
  • Apotex Inc (Canada)
  • Mylan N.V. (US)
  • Vir Biotechnology Inc (US) and others major key players.

Key Industry Development in Antiviral Drugs Market

  • In September 2024, Hyundai Bioscience announced XAFTY®, a broad-spectrum antiviral effective against COVID-19, mpox, dengue, and H1N1, at the "Disease Prevention and Control Summit 2024." Currently in Phase 3 trials, XAFTY® aims to transform the antiviral drug market with its multi-target approach and advanced delivery technology.
  • In April 2024, Onconova Therapeutics and Trawsfynydd Therapeutics announced a merger to form Traws Pharma, focusing on developing best-in-class antivirals. The combined company, with $28 million in funding from a private placement led by OrbiMed and Torrey Pines, will advance its antiviral assets, including viroksavir for influenza, travaltrelvir for COVID-19, and narazaciclib for endometrial cancer. With multiple clinical data catalysts expected in 2024, Traws Pharma aims to be a key player in the antiviral drug market.

Global Antiviral Drugs Market

Base Year:

2023

Forecast Period:

2024-2032

Historical Data:

2017 to 2023

Market Size in 2023:

USD 64.11 Bn.

Forecast Period 2024-32 CAGR:

4.7%

Market Size in 2032:

USD 96.93 Bn.

Segments Covered:

By Type

  • Branded
  • Generics

By Application

  • Influenza
  • HIV
  • Hepatitis
  • Coronavirus Infection
  • Human Papillomavirus
  • Others

By Age Group 

  • Adult
  • Pediatric

By Mechanism of Action 

  • DNA Polymerase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Neuraminidase Inhibitors
  • Others

By Region

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
  • Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:

  • Significant Rise in the Number of Viral Disease Outbreaks Driving the Growth of Market

Key Market Restraints:

  • The Lack of Rapid Diagnostic Tests to Identify Viruses is Hampering the Market Growth

Key Opportunities:

  • Rise in the Number of R&D Activities

Companies Covered in the report:

  • Gilead Sciences Inc (US), GlaxoSmithKline plc (UK), Johnson & Johnson Services Inc (US), AstraZeneca (UK), AbbVie Inc (US), and Other Major Players.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Type
 3.2 By Application
 3.3 By Age Group
 3.4 By Mechanism of Action

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Antiviral Drugs Market by Type
 5.1 Antiviral Drugs Market Overview Snapshot and Growth Engine
 5.2 Antiviral Drugs Market Overview
 5.3 Branded
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Branded: Grographic Segmentation
 5.4 Generics
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Generics: Grographic Segmentation

Chapter 6: Antiviral Drugs Market by Application
 6.1 Antiviral Drugs Market Overview Snapshot and Growth Engine
 6.2 Antiviral Drugs Market Overview
 6.3 Influenza
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Influenza: Grographic Segmentation
 6.4 HIV
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 HIV: Grographic Segmentation
 6.5 Hepatitis
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Hepatitis: Grographic Segmentation
 6.6 Herpes Simplex Virus {HSV}
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size (2017-2032F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Herpes Simplex Virus {HSV}: Grographic Segmentation
 6.7 Coronavirus Infection
  6.7.1 Introduction and Market Overview
  6.7.2 Historic and Forecasted Market Size (2017-2032F)
  6.7.3 Key Market Trends, Growth Factors and Opportunities
  6.7.4 Coronavirus Infection: Grographic Segmentation
 6.8 Human Papillomavirus
  6.8.1 Introduction and Market Overview
  6.8.2 Historic and Forecasted Market Size (2017-2032F)
  6.8.3 Key Market Trends, Growth Factors and Opportunities
  6.8.4 Human Papillomavirus: Grographic Segmentation
 6.9 Others
  6.9.1 Introduction and Market Overview
  6.9.2 Historic and Forecasted Market Size (2017-2032F)
  6.9.3 Key Market Trends, Growth Factors and Opportunities
  6.9.4 Others: Grographic Segmentation

Chapter 7: Antiviral Drugs Market by Age Group
 7.1 Antiviral Drugs Market Overview Snapshot and Growth Engine
 7.2 Antiviral Drugs Market Overview
 7.3 Adult
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size (2017-2032F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Adult: Grographic Segmentation
 7.4 Pediatric
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size (2017-2032F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Pediatric: Grographic Segmentation

Chapter 8: Antiviral Drugs Market by Mechanism of Action
 8.1 Antiviral Drugs Market Overview Snapshot and Growth Engine
 8.2 Antiviral Drugs Market Overview
 8.3 DNA Polymerase Inhibitors
  8.3.1 Introduction and Market Overview
  8.3.2 Historic and Forecasted Market Size (2017-2032F)
  8.3.3 Key Market Trends, Growth Factors and Opportunities
  8.3.4 DNA Polymerase Inhibitors: Grographic Segmentation
 8.4 Reverse Transcriptase Inhibitors
  8.4.1 Introduction and Market Overview
  8.4.2 Historic and Forecasted Market Size (2017-2032F)
  8.4.3 Key Market Trends, Growth Factors and Opportunities
  8.4.4 Reverse Transcriptase Inhibitors: Grographic Segmentation
 8.5 Protease Inhibitors
  8.5.1 Introduction and Market Overview
  8.5.2 Historic and Forecasted Market Size (2017-2032F)
  8.5.3 Key Market Trends, Growth Factors and Opportunities
  8.5.4 Protease Inhibitors: Grographic Segmentation
 8.6 Neuraminidase Inhibitors
  8.6.1 Introduction and Market Overview
  8.6.2 Historic and Forecasted Market Size (2017-2032F)
  8.6.3 Key Market Trends, Growth Factors and Opportunities
  8.6.4 Neuraminidase Inhibitors: Grographic Segmentation
 8.7 Integrase inhibitors
  8.7.1 Introduction and Market Overview
  8.7.2 Historic and Forecasted Market Size (2017-2032F)
  8.7.3 Key Market Trends, Growth Factors and Opportunities
  8.7.4 Integrase inhibitors: Grographic Segmentation
 8.8 Attachment inhibitors
  8.8.1 Introduction and Market Overview
  8.8.2 Historic and Forecasted Market Size (2017-2032F)
  8.8.3 Key Market Trends, Growth Factors and Opportunities
  8.8.4 Attachment inhibitors: Grographic Segmentation
 8.9 Others
  8.9.1 Introduction and Market Overview
  8.9.2 Historic and Forecasted Market Size (2017-2032F)
  8.9.3 Key Market Trends, Growth Factors and Opportunities
  8.9.4 Others: Grographic Segmentation

Chapter 9: Company Profiles and Competitive Analysis
 9.1 Competitive Landscape
  9.1.1 Competitive Positioning
  9.1.2 Antiviral Drugs Sales and Market Share By Players
  9.1.3 Industry BCG Matrix
  9.1.4 Ansoff Matrix
  9.1.5 Antiviral Drugs Industry Concentration Ratio (CR5 and HHI)
  9.1.6 Top 5 Antiviral Drugs Players Market Share
  9.1.7 Mergers and Acquisitions
  9.1.8 Business Strategies By Top Players
 9.2 GILEAD SCIENCES INC
  9.2.1 Company Overview
  9.2.2 Key Executives
  9.2.3 Company Snapshot
  9.2.4 Operating Business Segments
  9.2.5 Product Portfolio
  9.2.6 Business Performance
  9.2.7 Key Strategic Moves and Recent Developments
  9.2.8 SWOT Analysis
 9.3 GLAXOSMITHKLINE PLC
 9.4 JOHNSON & JOHNSON SERVICES INC
 9.5 ASTRAZENECA
 9.6 ABBVIE INC
 9.7 MERCK & CO INC
 9.8 TEVA PHARMACEUTICAL INDUSTRIES LTD
 9.9 REGENERON PHARMACEUTICALS INC
 9.10 BRISTOL-MYERS SQUIBB COMPANY
 9.11 ZYDUS CADILA
 9.12 CIPLA INC
 9.13 PRINSTON PHARMACEUTICAL INC
 9.14 HETERO
 9.15 AUROBINDO PHARMA
 9.16 APOTEX INC
 9.17 MYLAN N.V.
 9.18 VIR BIOTECHNOLOGY INC.
 9.19 OTHER MAJOR PLAYERS

Chapter 10: Global Antiviral Drugs Market Analysis, Insights and Forecast, 2017-2032
 10.1 Market Overview
 10.2 Historic and Forecasted Market Size By Type
  10.2.1 Branded
  10.2.2 Generics
 10.3 Historic and Forecasted Market Size By Application
  10.3.1 Influenza
  10.3.2 HIV
  10.3.3 Hepatitis
  10.3.4 Herpes Simplex Virus {HSV}
  10.3.5 Coronavirus Infection
  10.3.6 Human Papillomavirus
  10.3.7 Others
 10.4 Historic and Forecasted Market Size By Age Group
  10.4.1 Adult
  10.4.2 Pediatric
 10.5 Historic and Forecasted Market Size By Mechanism of Action
  10.5.1 DNA Polymerase Inhibitors
  10.5.2 Reverse Transcriptase Inhibitors
  10.5.3 Protease Inhibitors
  10.5.4 Neuraminidase Inhibitors
  10.5.5 Integrase inhibitors
  10.5.6 Attachment inhibitors
  10.5.7 Others

Chapter 11: North America Antiviral Drugs Market Analysis, Insights and Forecast, 2017-2032
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Type
  11.4.1 Branded
  11.4.2 Generics
 11.5 Historic and Forecasted Market Size By Application
  11.5.1 Influenza
  11.5.2 HIV
  11.5.3 Hepatitis
  11.5.4 Herpes Simplex Virus {HSV}
  11.5.5 Coronavirus Infection
  11.5.6 Human Papillomavirus
  11.5.7 Others
 11.6 Historic and Forecasted Market Size By Age Group
  11.6.1 Adult
  11.6.2 Pediatric
 11.7 Historic and Forecasted Market Size By Mechanism of Action
  11.7.1 DNA Polymerase Inhibitors
  11.7.2 Reverse Transcriptase Inhibitors
  11.7.3 Protease Inhibitors
  11.7.4 Neuraminidase Inhibitors
  11.7.5 Integrase inhibitors
  11.7.6 Attachment inhibitors
  11.7.7 Others
 11.8 Historic and Forecast Market Size by Country
  11.8.1 U.S.
  11.8.2 Canada
  11.8.3 Mexico

Chapter 12: Europe Antiviral Drugs Market Analysis, Insights and Forecast, 2017-2032
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Type
  12.4.1 Branded
  12.4.2 Generics
 12.5 Historic and Forecasted Market Size By Application
  12.5.1 Influenza
  12.5.2 HIV
  12.5.3 Hepatitis
  12.5.4 Herpes Simplex Virus {HSV}
  12.5.5 Coronavirus Infection
  12.5.6 Human Papillomavirus
  12.5.7 Others
 12.6 Historic and Forecasted Market Size By Age Group
  12.6.1 Adult
  12.6.2 Pediatric
 12.7 Historic and Forecasted Market Size By Mechanism of Action
  12.7.1 DNA Polymerase Inhibitors
  12.7.2 Reverse Transcriptase Inhibitors
  12.7.3 Protease Inhibitors
  12.7.4 Neuraminidase Inhibitors
  12.7.5 Integrase inhibitors
  12.7.6 Attachment inhibitors
  12.7.7 Others
 12.8 Historic and Forecast Market Size by Country
  12.8.1 Germany
  12.8.2 U.K.
  12.8.3 France
  12.8.4 Italy
  12.8.5 Russia
  12.8.6 Spain
  12.8.7 Rest of Europe

Chapter 13: Asia-Pacific Antiviral Drugs Market Analysis, Insights and Forecast, 2017-2032
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Type
  13.4.1 Branded
  13.4.2 Generics
 13.5 Historic and Forecasted Market Size By Application
  13.5.1 Influenza
  13.5.2 HIV
  13.5.3 Hepatitis
  13.5.4 Herpes Simplex Virus {HSV}
  13.5.5 Coronavirus Infection
  13.5.6 Human Papillomavirus
  13.5.7 Others
 13.6 Historic and Forecasted Market Size By Age Group
  13.6.1 Adult
  13.6.2 Pediatric
 13.7 Historic and Forecasted Market Size By Mechanism of Action
  13.7.1 DNA Polymerase Inhibitors
  13.7.2 Reverse Transcriptase Inhibitors
  13.7.3 Protease Inhibitors
  13.7.4 Neuraminidase Inhibitors
  13.7.5 Integrase inhibitors
  13.7.6 Attachment inhibitors
  13.7.7 Others
 13.8 Historic and Forecast Market Size by Country
  13.8.1 China
  13.8.2 India
  13.8.3 Japan
  13.8.4 Singapore
  13.8.5 Australia
  13.8.6 New Zealand
  13.8.7 Rest of APAC

Chapter 14: Middle East & Africa Antiviral Drugs Market Analysis, Insights and Forecast, 2017-2032
 14.1 Key Market Trends, Growth Factors and Opportunities
 14.2 Impact of Covid-19
 14.3 Key Players
 14.4 Key Market Trends, Growth Factors and Opportunities
 14.4 Historic and Forecasted Market Size By Type
  14.4.1 Branded
  14.4.2 Generics
 14.5 Historic and Forecasted Market Size By Application
  14.5.1 Influenza
  14.5.2 HIV
  14.5.3 Hepatitis
  14.5.4 Herpes Simplex Virus {HSV}
  14.5.5 Coronavirus Infection
  14.5.6 Human Papillomavirus
  14.5.7 Others
 14.6 Historic and Forecasted Market Size By Age Group
  14.6.1 Adult
  14.6.2 Pediatric
 14.7 Historic and Forecasted Market Size By Mechanism of Action
  14.7.1 DNA Polymerase Inhibitors
  14.7.2 Reverse Transcriptase Inhibitors
  14.7.3 Protease Inhibitors
  14.7.4 Neuraminidase Inhibitors
  14.7.5 Integrase inhibitors
  14.7.6 Attachment inhibitors
  14.7.7 Others
 14.8 Historic and Forecast Market Size by Country
  14.8.1 Turkey
  14.8.2 Saudi Arabia
  14.8.3 Iran
  14.8.4 UAE
  14.8.5 Africa
  14.8.6 Rest of MEA

Chapter 15: South America Antiviral Drugs Market Analysis, Insights and Forecast, 2017-2032
 15.1 Key Market Trends, Growth Factors and Opportunities
 15.2 Impact of Covid-19
 15.3 Key Players
 15.4 Key Market Trends, Growth Factors and Opportunities
 15.4 Historic and Forecasted Market Size By Type
  15.4.1 Branded
  15.4.2 Generics
 15.5 Historic and Forecasted Market Size By Application
  15.5.1 Influenza
  15.5.2 HIV
  15.5.3 Hepatitis
  15.5.4 Herpes Simplex Virus {HSV}
  15.5.5 Coronavirus Infection
  15.5.6 Human Papillomavirus
  15.5.7 Others
 15.6 Historic and Forecasted Market Size By Age Group
  15.6.1 Adult
  15.6.2 Pediatric
 15.7 Historic and Forecasted Market Size By Mechanism of Action
  15.7.1 DNA Polymerase Inhibitors
  15.7.2 Reverse Transcriptase Inhibitors
  15.7.3 Protease Inhibitors
  15.7.4 Neuraminidase Inhibitors
  15.7.5 Integrase inhibitors
  15.7.6 Attachment inhibitors
  15.7.7 Others
 15.8 Historic and Forecast Market Size by Country
  15.8.1 Brazil
  15.8.2 Argentina
  15.8.3 Rest of SA

Chapter 16 Investment Analysis

Chapter 17 Analyst Viewpoint and Conclusion

Global Antiviral Drugs Market

Base Year:

2023

Forecast Period:

2024-2032

Historical Data:

2017 to 2023

Market Size in 2023:

USD 64.11 Bn.

Forecast Period 2024-32 CAGR:

4.7%

Market Size in 2032:

USD 96.93 Bn.

Segments Covered:

By Type

  • Branded
  • Generics

By Application

  • Influenza
  • HIV
  • Hepatitis
  • Coronavirus Infection
  • Human Papillomavirus
  • Others

By Age Group 

  • Adult
  • Pediatric

By Mechanism of Action 

  • DNA Polymerase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Neuraminidase Inhibitors
  • Others

By Region

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
  • Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:

  • Significant Rise in the Number of Viral Disease Outbreaks Driving the Growth of Market

Key Market Restraints:

  • The Lack of Rapid Diagnostic Tests to Identify Viruses is Hampering the Market Growth

Key Opportunities:

  • Rise in the Number of R&D Activities

Companies Covered in the report:

  • Gilead Sciences Inc (US), GlaxoSmithKline plc (UK), Johnson & Johnson Services Inc (US), AstraZeneca (UK), AbbVie Inc (US), and Other Major Players.
Please Wait...

Frequently Asked Questions :

What would be the forecast period in the Antiviral Drugs Market research report?

The forecast period in the Antiviral Drugs Market research report is 2024-2032.

Who are the key players in Antiviral Drugs Market?

Gilead Sciences Inc (US), GlaxoSmithKline plc (UK), Johnson & Johnson Services Inc (US), AstraZeneca (UK), AbbVie Inc (US), Merck & Co Inc (US), Teva Pharmaceutical Industries Ltd (Israel) Regeneron Pharmaceuticals Inc (US), Bristol-Myers Squibb Company (US), Zydus Cadila (India), Cipla Inc (India), Prinston Pharmaceutical Inc (US), Hetero (India), Aurobindo Pharma (India), Apotex Inc (Canada), Mylan N.V. (US), Vir Biotechnology Inc (US), and Other Major Players.

What are the segments of Antiviral Drugs Market?

Antiviral Drugs Market is segmented into Type, Application, Age Group, Mechanism of Action and region. By Type, the market is categorized into Branded, Generics. By Application, the market is categorized into Influenza, HIV, Hepatitis, Coronavirus Infection, Human Papillomavirus, Others. By Age Group the market is categorized into Adult, Pediatric. By Mechanism of Action, the market is categorized into DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Others. By region, it is analysed across North America (U.S.; Canada; Mexico), Europe (Germany; U.K.; France; Italy; Russia; Spain, etc.), Asia-Pacific (China; India; Japan; Southeast Asia, etc.), South America (Brazil; Argentina, etc.), Middle East & Africa (Saudi Arabia; South Africa, etc.).

What is the Antiviral Drugs Market?

Antiviral drugs are a class of medication that is used to kill or suppress the ability of a virus to replicate hence it prohibits the virus potential to proliferate and reproduce. Viruses are made of genetic material such as DNA or RNA which is alive when it is outside in the environment but gains its ability to reproduce and proliferate when it enters a susceptible host.

How big is Antiviral Drugs Market?

Global Antiviral Drugs Market was valued at USD 64.11 Billion in 2023 and is expected to reach USD 96.93 Billion by the year 2032, at a CAGR of 4.7%.